Abstract
RASopathies, such as HRAS related Costello syndrome, have a wide range of presentations with infantile hypertrophic cardiomyopathy as one of the most life-limiting features. While data for Costello Syndrome is lacking, one-year survival of infantile hypertrophic cardiomyopathy in patients with Noonan syndrome is only 31%. The common comorbidity of treatment resistant non-reentrant atrial tachycardia further complicates Costello syndrome. A unique area of hope in the treatment of infantile hypertrophic cardiomyopathy due to RASopathies is MEK inhibitors such as trametinib, which block the direct downstream effects of RAS overactivation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
